Triglyceride-containing lipoprotein sub-fractions and risk of coronary heart disease and stroke: A prospective analysis in 11,560 adults

Aims Elevated low-density lipoprotein cholesterol (LDL-C) is a risk factor for cardiovascular disease; however, there is uncertainty about the role of total triglycerides and the individual triglyceride-containing lipoprotein sub-fractions. We measured 14 triglyceride-containing lipoprotein sub-fractions using nuclear magnetic resonance and examined associations with coronary heart disease and stroke. Methods Triglyceride-containing sub-fraction measures were available in 11,560 participants from the three UK cohorts free of coronary heart disease and stroke at baseline. Multivariable logistic regression was used to estimate the association of each sub-fraction with coronary heart disease and stroke expressed as the odds ratio per standard deviation increment in the corresponding measure. Results The 14 triglyceride-containing sub-fractions were positively correlated with one another and with total triglycerides, and inversely correlated with high-density lipoprotein cholesterol (HDL-C). Thirteen sub-fractions were positively associated with coronary heart disease (odds ratio in the range 1.12 to 1.22), with the effect estimates for coronary heart disease being comparable in subgroup analysis of participants with and without type 2 diabetes, and were attenuated after adjustment for HDL-C and LDL-C. There was no evidence for a clear association of any triglyceride lipoprotein sub-fraction with stroke. Conclusions Triglyceride sub-fractions are associated with increased risk of coronary heart disease but not stroke, with attenuation of effects on adjustment for HDL-C and LDL-C.

[1]  B. Nordestgaard,et al.  A third of nonfasting plasma cholesterol is in remnant lipoproteins: Lipoprotein subclass profiling in 9293 individuals. , 2019, Atherosclerosis.

[2]  Deepak L. Bhatt,et al.  Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia , 2019, The New England journal of medicine.

[3]  R. Collins,et al.  Lipids, Lipoproteins, and Metabolites and Risk of Myocardial Infarction and Stroke , 2018, Journal of the American College of Cardiology.

[4]  Brian A Ference,et al.  Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk , 2017, JAMA.

[5]  R. Hegele,et al.  Genetics of Triglycerides and the Risk of Atherosclerosis , 2017, Current Atherosclerosis Reports.

[6]  A. von Eckardstein,et al.  HDL cholesterol: reappraisal of its clinical relevance , 2017, Clinical Research in Cardiology.

[7]  Po-Yin Chang,et al.  Triglyceride and HDL-C Dyslipidemia and Risks of Coronary Heart Disease and Ischemic Stroke by Glycemic Dysregulation Status: The Strong Heart Study , 2017, Diabetes Care.

[8]  S. Humphries,et al.  Association of Lipid Fractions With Risks for Coronary Artery Disease and Diabetes. , 2016, JAMA cardiology.

[9]  B. Nordestgaard.  Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology. , 2016, Circulation research.

[10]  Barry J. Davis,et al.  Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials , 2015, The Lancet.

[11]  Tom R. Gaunt,et al.  Metabolite profiling and cardiovascular event risk: a prospective study of 3 population-based cohorts. , 2015, Circulation.

[12]  Pasi Soininen,et al.  Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics. , 2015, Circulation. Cardiovascular genetics.

[13]  Anette Varbo,et al.  Triglycerides and cardiovascular disease , 2014, The Lancet.

[14]  B. Nordestgaard,et al.  Remnant cholesterol and ischemic heart disease , 2014, Current opinion in lipidology.

[15]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[16]  Tom R. Gaunt,et al.  Population Genomics of Cardiometabolic Traits: Design of the University College London-London School of Hygiene and Tropical Medicine-Edinburgh-Bristol (UCLEB) Consortium , 2013, PLoS ONE.

[17]  Pasi Soininen,et al.  Quantitative high-throughput metabolomics: a new era in epidemiology and genetics , 2012, Genome Medicine.

[18]  Nish Chaturvedi,et al.  Southall And Brent REvisited: Cohort profile of SABRE, a UK population-based comparison of cardiovascular disease and diabetes in people of European, Indian Asian and African Caribbean origins. , 2012, International journal of epidemiology.

[19]  Moshe Levi,et al.  Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. , 2011, Circulation.

[20]  P. Barberger‐Gateau,et al.  Triglycerides and risk of hemorrhagic stroke vs. ischemic vascular events: The Three-City Study. , 2010, Atherosclerosis.

[21]  G. Moneta,et al.  Major Lipids, Apolipoproteins, and Risk of Vascular Disease , 2010 .

[22]  J. Danesh,et al.  Major lipids, apolipoproteins, and risk of vascular disease. , 2009, JAMA.

[23]  Reino Laatikainen,et al.  High-throughput serum NMR metabonomics for cost-effective holistic studies on systemic metabolism. , 2009, The Analyst.

[24]  B. Nordestgaard,et al.  Improving Prediction of Ischemic Cardiovascular Disease in the General Population Using Apolipoprotein B: The Copenhagen City Heart Study , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[25]  M. Pfeffer,et al.  VLDL, Apolipoproteins B, CIII, and E, and Risk of Recurrent Coronary Events in the Cholesterol and Recurrent Events (CARE) Trial , 2000, Circulation.

[26]  S J Pocock,et al.  British Regional Heart Study: cardiovascular risk factors in middle-aged men in 24 towns. , 1981, British medical journal.

[27]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.